Mazdutide
A GLP-1 / glucagon dual agonist developed for obesity and metabolic dysfunction in Asian populations.
How it works
Mazdutide (IBI362) activates GLP-1 and glucagon receptors. The glucagon arm promotes hepatic lipid oxidation and elevates resting metabolic rate while GLP-1 suppresses appetite and improves glycemia.
Reported benefits
- Phase-2 weight loss up to 11.3% at 24 weeks with 9 mg weekly
- Reduction of hepatic fat content
- Favourable lipid profile changes
Dosage & administration
Investigational. Phase-2 protocols used 3 mg, 4.5 mg, 6 mg, and 9 mg weekly with stepwise escalation.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Mazdutide in Chinese adults with overweight or obesity
Nature Communications · 2023
248 adults achieved up to 11.3% weight reduction at 24 weeks.
Safety & warnings
- GI events similar to other incretin agonists
- Transient heart-rate elevation
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
10 mg
MDT10
Box of 10 · $585
Single vial · $1,170
Related guides
Tirzepatide
A first-in-class dual GIP and GLP-1 receptor agonist that has reset the standard for pharmacologic weight loss.
Semaglutide
The long-acting GLP-1 analogue that opened the modern era of injectable weight management.
Retatrutide
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing unprecedented weight loss in phase-2 data.